167 related articles for article (PubMed ID: 11676350)
1. Urine tissue-polypeptide-specific antigen (TPS) as a marker for bladder cancer.
Boman H; Hedelin H; Holmäng S
Scand J Urol Nephrol; 2001 Sep; 35(4):270-4. PubMed ID: 11676350
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of tissue-polypeptide specific antigen (TPS) in bladder cancer.
Menendez V; Galan JA; Fernandez-Suarez A; Lopez S; Alcover J; Calpena R; Filella X
Anticancer Res; 2002; 22(6B):3713-6. PubMed ID: 12552981
[TBL] [Abstract][Full Text] [Related]
3. Urinary tissue polypeptide-specific antigen for the diagnosis of bladder cancer.
Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; García J; Alférez F; González deBuitrago JM; Navajo JA
Urology; 2000 Apr; 55(4):526-32. PubMed ID: 10736496
[TBL] [Abstract][Full Text] [Related]
4. [Bladder cancer screening with urine-based tumour markers - occupational medical experience].
Nasterlack M; Feil G; Leng G; Pesch B; Huber S; Sievert KD; Johnen G; Taeger D; Mayer T; Kluckert M; Brüning T; Stenzl A
Aktuelle Urol; 2011 Mar; 42(2):128-34. PubMed ID: 21437837
[TBL] [Abstract][Full Text] [Related]
5. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
[TBL] [Abstract][Full Text] [Related]
7. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
8. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
Poulakis V; Witzsch U; De Vries R; Altmannsberger HM; Manyak MJ; Becht E
BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
[TBL] [Abstract][Full Text] [Related]
9. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.
Boman H; Hedelin H; Holmäng S
J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280
[TBL] [Abstract][Full Text] [Related]
10. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
[TBL] [Abstract][Full Text] [Related]
11. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.
Grossman HB; Soloway M; Messing E; Katz G; Stein B; Kassabian V; Shen Y
JAMA; 2006 Jan; 295(3):299-305. PubMed ID: 16418465
[TBL] [Abstract][Full Text] [Related]
12. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
[TBL] [Abstract][Full Text] [Related]
14. FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
Beukers W; van der Keur KA; Kandimalla R; Vergouwe Y; Steyerberg EW; Boormans JL; Jensen JB; Lorente JA; Real FX; Segersten U; Orntoft TF; Malats N; Malmström PU; Dyrskjot L; Zwarthoff EC
J Urol; 2017 Jun; 197(6):1410-1418. PubMed ID: 28049011
[TBL] [Abstract][Full Text] [Related]
15. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
[TBL] [Abstract][Full Text] [Related]
16. Urine detection of survivin and diagnosis of bladder cancer.
Smith SD; Wheeler MA; Plescia J; Colberg JW; Weiss RM; Altieri DC
JAMA; 2001 Jan; 285(3):324-8. PubMed ID: 11176843
[TBL] [Abstract][Full Text] [Related]
17. Urinary levels of tumour associated antigens (CA 19-9, TPA and CEA) in patients with neoplastic and non-neoplastic urothelial abnormalities.
Casetta G; Piana P; Cavallini A; Vottero M; Tizzani A
Br J Urol; 1993 Jul; 72(1):60-4. PubMed ID: 8149183
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor in urine from patients with bladder cancer.
Saika T; Tsushima T; Nasu Y; Kumon H; Ohmori H
Urol Res; 2000 Aug; 28(4):230-4. PubMed ID: 11011960
[TBL] [Abstract][Full Text] [Related]
19. [Can the combination of bladder ultrasonography and urinary cytodiagnosis replace cystoscopy in the diagnosis and follow-up of tumors of the bladder?].
Cariou G; Maaraoui N; Cortesse A
Prog Urol; 1997 Feb; 7(1):51-5. PubMed ID: 9116739
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the clinical value of urinary NMP22 as a marker in the screening and surveillance of transitional cell carcinoma of the urinary bladder.
Chahal R; Darshane A; Browning AJ; Sundaram SK
Eur Urol; 2001 Oct; 40(4):415-20; discussion 421. PubMed ID: 11713396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
